Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept’s Early NASH Efforts Will Stress Advanced Fibrosis

Dec 17 2019

• By Joseph Haas

SC1912_Product Launch_380643976_1200.jpg — Intercept outlined its launch plans for OCA in NASH

Related Content

NASH Pipeline Includes Six Candidates That Have Reached Phase III

Oct 01 2019

Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated

Nov 11 2019

Intercept Retakes The Lead In NASH

Feb 19 2019

Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Oct 17 2019

Gilead’s Bad Luck In NASH Continues With ATLAS Failure

Dec 16 2019

Intercept’s NASH Drug Delayed By April Advisory Committee, But Firm Is Ready For Launch

Dec 16 2019

Related Companies

Intercept Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Genfit SA

Additional Topics

Business Strategies Launches Commercial BioPharmaceutical Liver & Hepatic

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window